恩替卡韦治疗失代偿期乙型肝炎肝硬化的临床观察

目的：探讨恩替卡韦治疗乙型肝炎后肝硬化的临床疗果。方法：选择乙型肝炎后肝硬化男性患者84例，随机分为两组，对照组采用常规保肝对症治疗，治疗组在常规治疗基础上加用恩替卡韦。观察治疗后各项指标变化。结果：①治疗组HBV—DNA水平显著下降，与对照组比较，差异有统计学意义（P〈0．05）；②治疗组血清生化显著下降，与对照组比较差异有统计学意义（P〈0．05）；③两组患者病程及病情进展比较，差异有统计学意义（P〈0．05）。结论：恩替卡韦治疗乙型肝炎后肝硬化能有效快速抑制病毒复制，改善肝功能，可改善短期及长期预后。

Entecavir for the treatment of hepatitis B with decompensated cirrhosis

Objective： To explore the clinical efficacy of Entecavir in the treatment of hepatitis B with decompensated cirrhosis. Methods： Eighty--four patients with hepatitis B with decompensated cirrhosis were randomly divided into treatment group （n=42） treated with Entecavir and conventional therapy, and control group （n=42） treated with conventional therapy only. The HBV DNA, liver function and Child-- Pugh scores were observed. Results：Compared with control, the HBV DNA level was significantly reduced in treatment group （P〈0. 05）, and the serum biochemical parameters including ALT, AST and total bilirubin were significantly decreased （P〈0.05）. There were statistical differences in disease course and progression between the two groups （P〈0. 05）. Conclusion： The Entecavir can effectively inhibit the replication of hepatitis B virus, rapidly improve the liver function and delay the progression of liver cirrhosis for patients with decompensated cirrhosis.